Table 4 Treatment-related adverse events (TRAEs) and immune-related adverse events (irAEs) in neoadjuvant stage
ICT group (n = 52), n (%) | CRT group (n = 51), n (%) | |||||
|---|---|---|---|---|---|---|
Any grade | Grade 1–2 | Grade ≥ 3 | Any grade | Grade 1–2 | Grade ≥ 3 | |
Any TRAEs | 50 (96.2) | 40 (76.9) | 10 (19.2) | 51 (100.0) | 34 (66.7) | 17 (33.3) |
Nausea | 39 (75.0) | 39 (75.0) | 0 | 32 (62.7) | 32 (62.7) | 0 |
Vomiting | 37 (71.2) | 37 (71.2) | 0 | 22 (43.1) | 22 (43.1) | 0 |
Anemia | 24 (46.2) | 23 (44.2) | 1 (1.9) | 25 (49.0) | 24 (47.1) | 1 (2.0) |
Hypoalbuminemia | 20 (38.5) | 20 (38.5) | 0 | 20 (39.2) | 19 (37.3) | 1 (2.0) |
Fatigue | 11 (21.2) | 11 (21.2) | 0 | 10 (19.6) | 10 (19.6) | 0 |
Decreased appetite | 10 (19.2) | 10 (19.2) | 0 | 21 (41.2) | 21 (41.2) | 0 |
Reactive cutaneous capillary endothelial proliferation | 10 (19.2) | 10 (19.2) | 0 | 0 (0.0) | 0 (0.0) | 0 |
Elevated γ-Glutamyl transferase | 10 (19.2) | 10 (19.2) | 0 | 4 (7.8) | 4 (7.8) | 0 |
Decreased white blood cell count | 9 (17.3) | 2 (3.8) | 7 (13.5) | 40 (78.4) | 29 (56.9) | 11 (21.6) |
Elevated alanine aminotransferase | 7 (13.5) | 6 (11.5) | 1 (1.9) | 1 (2.0) | 1 (2.0) | 0 |
Decreased neutrophil count | 6 (11.5) | 4 (7.7) | 2 (3.8) | 24 (47.1) | 19 (37.3) | 5 (9.8) |
Hyperuricemia | 6 (11.5) | 6 (11.5) | 0 | 3 (5.9) | 2 (3.9) | 1 (2.0) |
Decreased platelet count | 4 (7.7) | 3 (5.8) | 1 (1.9) | 24 (47.1) | 20 (39.2) | 4 (7.8) |
Pain | 4 (7.7) | 4 (7.7) | 0 | 7 (13.7) | 6 (11.8) | 1 (2.0) |
Elevated blood bilirubin levels | 4 (7.7) | 4 (7.7) | 0 | 5 (9.8) | 5 (9.8) | 0 |
Constipation | 3 (5.8) | 3 (5.8) | 0 | 6 (11.8) | 6 (11.8) | 0 |
Radiation esophagitis | 0 | 0 | 0 | 19 (37.3) | 19 (37.3) | 0 |
Insomnia | 0 | 0 | 0 | 6 (11.8) | 6 (11.8) | 0 |
Any irAE | 18 (34.6) | 16 (30.8) | 2 (3.8) | NA | NA | NA |
Reactive cutaneous capillary endothelial proliferation | 10 (19.2) | 10 (19.2) | 0 | NA | NA | NA |
Immune-mediated pulmonary disease | 3 (5.8) | 3 (5.8) | 0 | NA | NA | NA |
